Jul. 25 at 12:07 PM
Cantor reiterated
$JANX Overweight-
$200 and said, "
$JANX unveiled 3 new early-stage pipeline programs after the close."
$JNJ $RHHBY $ABBV $GMAB VIR CNTX MRK LVTX
Cantor added, "In the context of the validation of its
masked TCE platform from strong clinical data for JANX007 (PSMA x CD3 TCE), each of the programs resonates with us. They showcase both the versatility/modularity of the company's platform, as well as the company's creative ability to solve difficult biology challenges.
Why now? Investor focus is obviously squarely on '007 so that these updates likely won't move the valuation needle much - but the company had committed to this R&D update at the start of the year. The company was emphatic that this pipeline update is coming from strength and confidence in '007 - and not meant to divert attention from it. With clinical trials expected to get underway over the next 1-4 quarters, this was seen as a prudent time to profile them."
